Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation

List of Tables

The Global Liquid Biopsy Market is forecasted to grow significantly, with a projected USD 1,704.64 million in 2023 at a CAGR of 20.37% and expected to reach a staggering USD 6,250.89 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Liquid Biopsy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Liquid Biopsy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, Exosome, and Extracellular Vesicles. The Cell-free DNA commanded largest market share of 18.34% in 2022, followed by Circulating Tumor DNA.

Based on Sample, market is studied across Blood Based and Urine Based. The Blood Based commanded largest market share of 52.12% in 2022, followed by Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services. The Assay Kits commanded largest market share of 44.23% in 2022, followed by Instruments.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The Single-gene Analysis using PCR Microarrays commanded largest market share of 62.12% in 2022, followed by Multi-gene Parallel Analysis using NGS.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer. The Non-Cancer Indication commanded largest market share of 61.23% in 2022, followed by Cancer Indication.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. The Clinical Diagnostic Laboratories commanded largest market share of 44.23% in 2022, followed by Hospitals.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring. The Treatment Monitoring commanded largest market share of 32.12% in 2022, followed by Early Cancer Screening.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 42.54% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Liquid Biopsy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Liquid Biopsy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liquid Biopsy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liquid Biopsy Market?

4. What is the competitive strategic window for opportunities in the Global Liquid Biopsy Market?

5. What are the technology trends and regulatory frameworks in the Global Liquid Biopsy Market?

6. What is the market share of the leading vendors in the Global Liquid Biopsy Market?

7. What modes and strategic moves are considered suitable for entering the Global Liquid Biopsy Market?

Product Code: MRR-43470FC608C9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Liquid Biopsy Market, by Biomarkers, 2022 vs 2030
4.3. Liquid Biopsy Market, by Sample, 2022 vs 2030
4.4. Liquid Biopsy Market, by Type, 2022 vs 2030
4.5. Liquid Biopsy Market, by Technology, 2022 vs 2030
4.6. Liquid Biopsy Market, by Indication, 2022 vs 2030
4.7. Liquid Biopsy Market, by End-User, 2022 vs 2030
4.8. Liquid Biopsy Market, by Application, 2022 vs 2030
4.9. Liquid Biopsy Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Incidence and Prevalence of Cancer
  - 5.1.1.2. Increasing Preference for Noninvasive Diagnostic Procedures
  - 5.1.1.3. Availability of Funding to Expand Cancer Research in the Field of Liquid Biopsy
- 5.1.2. Restraints
  - 5.1.2.1. Low Abundance and Fragile Nature of the Circulating Tumor Cells (CTCs)
- 5.1.3. Opportunities
  - 5.1.3.1. Significant use of Microarrays and Next-Generation Sequencing (NGS)
  - 5.1.3.2. Ongoing Development of Advanced Liquid Biopsy Assays
- 5.1.4. Challenges
  - 5.1.4.1. Unclear Regulatory and Reimbursement Scenario
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Liquid Biopsy Market, by Biomarkers

6.1. Introduction
6.2. Cell-free DNA
6.3. Circulating Tumor Cells
6.4. Circulating Tumor DNA
6.5. Exosome
6.6. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

7.1. Introduction
7.2. Blood Based
7.3. Urine Based

8. Liquid Biopsy Market, by Type

8.1. Introduction
8.2. Assay Kits
8.3. Instruments
8.4. Services

9. Liquid Biopsy Market, by Technology

9.1. Introduction
9.2. Multi-gene Parallel Analysis using NGS
9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

10.1. Introduction
10.2. Cancer Indication
- 10.2.1. Breast Cancer
- 10.2.2. Colorectal Cancer
- 10.2.3. Lung Cancer
- 10.2.4. Melanoma
- 10.2.5. Prostate Cancer
10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

11.1. Introduction
11.2. Academic & Research Centers
11.3. Clinical Diagnostic Laboratories
11.4. Hospitals
11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

12.1. Introduction
12.2. Early Cancer Screening
12.3. Recurrence Monitoring
12.4. Therapy Selection
12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States

14. Asia-Pacific Liquid Biopsy Market

14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom

16. Competitive Landscape

16.1. FPNV Positioning Matrix
16.2. Market Share Analysis, By Key Player
16.3. Competitive Scenario Analysis, By Key Player
- 16.3.1. Merger & Acquisition
  - 16.3.1.1. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research.
  - 16.3.1.2. Labcorp Completes Acquisition of Personal Genome Diagnostics.
- 16.3.2. Agreement, Collaboration, & Partnership
  - 16.3.2.1. Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test.
  - 16.3.2.2. Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug.
  - 16.3.2.3. Hamilton and BioFluidica Pen Next Generation Liquid Biopsy Platform Co-Marketing Agreement.
  - 16.3.2.4. Datar and Artemis DNA sign contract to offer cancer detection biopsies.
- 16.3.3. New Product Launch & Enhancement
  - 16.3.3.1. Startup Mantra: Making cancer detection more accessible.
  - 16.3.3.2. Novel urine-based liquid biopsy launched in US prostate cancer market.
  - 16.3.3.3. BillionToOne launches oncology liquid biopsy products for research use & announces clinical research collaboration with UCSD.
- 16.3.4. Investment & Funding
  - 16.3.4.1. Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers.

17. List of Company Mentioned

18. Appendix

18.1. Discussion Guide
18.2. License & Pricing